摘要
目的检测高危HPV感染的正常宫颈组织、宫颈癌前病变组织、宫颈癌组织HPV16E6和IDO的表达,分析二者在宫颈病变组织恶化过程中的关系,探讨其作为宫颈癌肿瘤标志物的可能性。方法把经第二代杂交捕获(HC-2)法行HPV DNA检测为高危型HPV感染的宫颈病变者120例为实验对象,正常宫颈组织、宫颈癌前病变组织、宫颈癌组织各40例。免疫组化染色法检测各组织中HPV16E6和IDO的表达情况。结果 40例正常宫颈组织中HPV16E6和IDO阳性表达率分别为7.5%、0%;40例宫颈癌前病变组织中HPV16E6和IDO阳性表达率分别为37.5%、22.5%。40例宫颈癌组织中HPV16E6和IDO阳性表达率分别为90%、 80%。在宫颈病变组织恶化过程中HPV16E6和IDO的阳性表达呈正相关(rs=0.710, P=0.000)。结论 HPV16E6和IDO的表达随宫颈病变的进展而呈现出阳性程度逐渐递增趋势,HPV16E6和IDO可考虑成为预测宫颈病变组织恶化的肿瘤标志物。
Objective To explore the potential of HPV16E6 and IDO as a tumor markers of cervical cancer,the expression of high-risk HPV-infected normal cervical tissue,cervical precancerous lesions,cervical cancer tissue HPV16E6 and IDO,the correlation between HPV16E6 and IDO in the progression of cervical lesions were analyzed.Methods 120 cases of cervical lesions with high-risk HPV infection detected by HPV DNA in the second generation hybrid capture(HC-2)method were used as experimental subjects,40 cases each in normal cervical tissue group,cervical precancerous lesions group and cervical cancer tissues group,respectively.The expression of HPV16E6 and IDO in each tissue group was detected by immunohistochemical staining.Results The expression rates of HPV16E6 and IDO in 40 cases of normal cervical tissues were 7.5%and 0%,respectively.The expression rates of HPV16E6 and IDO in 40 cases of cervical precancerous lesions were 37.5%and 22.5%,respectively.The positive expression rates of HPV16E6 and IDO in 40 cases of cervical cancer tissues were 90%and 80%,respectively.The positive expression of HPV16E6 and IDO was positively correlated in the progression of cervical lesions(rs=0.710,P=0.000).Conclusion The expression of HPV16E6 and IDO showed a positive trend with the progress of cervical lesions.HPV16E6 and IDO have the potential of tumor markers for predicting the progression cervical lesions.
作者
杨琳琳
尹春梅
张磊
王薇
赵凌锋
杨钰叠
赵赫
刘莹
YANG Lin-lin;YIN Chun-mei;ZHANG Lei;WANG Wei;ZHAO Ling-feng;YANG Yu-die;ZHAO He;LIU Ying(Dept.of Gynecology,The 3rd Affiliated Hospital of Kunming Medical University,The Cancer Hospital of Yunnan Province,Kunming Yunnan 650118,China)
出处
《昆明医科大学学报》
CAS
2020年第12期68-72,共5页
Journal of Kunming Medical University
基金
云南省卫生科技计划基金资助项目(2016NS091)
云南省高层次卫生健康技术人才培养专项基金资助项目(D-2018053)。